Skip to search formSkip to main contentSkip to account menu

OSI-774

Known as: OSI 774, OSI774 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Erlotinib Hydrochlorideerlotinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells.
2011
2011
Label-free electrochemical measurement of protein tyrosine kinase activity and inhibition based on electro-catalyzed tyrosine signaling.
Highly Cited
2005
Highly Cited
2005
Enhanced Sensitivity to the HER1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Hydrochloride in Chemotherapy-Resistant Tumor Cell Lines
Purpose: Erlotinib (Tarceva, OSI-774) is a potent and specific inhibitor of the HER1/epidermal growth factor receptor (EGFR… 
2004
2004
Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial…
2001 Background: Aberrant VEGFR expression in breast tumor cells and EGFR expression in endothelial cells may contribute to tumor… 
Review
2004
Review
2004
Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer.
Lung cancer is the leading cause of death worldwide. Current treatment modalities, including chemotherapy, radiotherapy and… 
Review
2003
Review
2003
Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).
The epidermal growth factor receptor (EGFR) is a transmembrane receptor involved in the regulation of a complex array of… 
2003
2003
Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough?
As the number of molecular-targeted agents under clinical development keeps growing, it is becoming increasingly evident that it… 
Review
2003
Review
2003
The epidermal growth factor receptor pathway and its inhibition as anticancer therapy.
Epidermal growth factor receptor (EGFR) is commonly overexpressed in a number of epithelial malignancies and is often associated… 
2002
2002
Lung cancer prevention: retinoids and the epidermal growth factor receptor-a phoenix rising?
The widespread use of tobacco in the 20th century has resulted in a lung cancer epidemic extending into the 21st century… 
Review
2001
Review
2001
OSI-774 OSI Pharmaceuticals.
OSI-774 (formerly CP-358774), a quinazoline derivative, is an orally active epidermal growth factor receptor (EGFR) inhibitor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)